

117TH CONGRESS
2D SESSION

H. R. 7640

To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as “orphan drugs”).

IN THE HOUSE OF REPRESENTATIVES

MAY 3, 2022

Mr. BILIRAKIS (for himself and Mr. BUTTERFIELD) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as “orphan drugs”).

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

1 **SECTION 1. REAUTHORIZATION OF GRANTS AND CON-**
2 **TRACTS FOR DEVELOPMENT OF ORPHAN**
3 **DRUGS.**

4 Section 5(c) of the Orphan Drug Act (21 U.S.C.
5 360ee(c)) is amended by striking “2018 through 2022”
6 and inserting “2023 through 2027”.

○